AZD0901 + AZD7789 + fluoropyrimidine

This is a **combination therapy** under clinical investigation for the treatment of *locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma*. It consists of three agents: - **AZD0901 (CMG901):** An antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2) on tumor cells, delivering the cytotoxic payload monomethyl auristatin E (MMAE). Its mechanisms of action include direct cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC)[1]. - **AZD7789 (sabestomig):** A bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), aiming to restore and enhance anti-tumor T cell activity by blocking these immune checkpoints[2][4][6]. - **Fluoropyrimidine:** Typically refers to 5-fluorouracil or its oral prodrug capecitabine, both small molecule chemotherapeutics inhibiting thymidylate synthase, thereby interfering with DNA synthesis in rapidly dividing cells[9]. The combination is being studied in multi-arm phase II clinical trials[9] for gastric/GEJ cancer, investigating efficacy, safety, tolerability, pharmacokinetics, and immunogenicity.

Other names

CMG901 (for AZD0901)sabestomig (for AZD7789)5-fluorouracil (for fluoropyrimidine)capecitabine (for fluoropyrimidine)